JGJérôme Garot

Jérôme Garot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jérôme Garot has a total of 289 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic Value of Late Gadolinium Enhancement Findings in Isolated Left Ventricular Dilatation and Dilated Cardiomyopathy.

    by Trecy Gonçalves, Suzanne Duhamel, Solenn Toupin, Francesca Sanguineti, Philippe Garot, Thierry Unterseeh, Thomas Hovasse, Mariama Akodad, Stéphane Champagne, Bernard Chevalier, et al.

  • Stress CMR ischaemic burden and long-term mortality in left ventricular systolic dysfunction: a multicentre registry study

    by Alexandre Pfeffer, JérÔme Garot, Suzanne Duhamel, Philippe Garot, Francesca Sanguineti, Thomas Hovasse, StépHane Champagne, Thierry Unterseeh, Mariama Akodad, Antoinette Neylon, et al.

    Aims: Stress perfusion cardiovascular magnetic resonance (CMR) integrates the assessment of myocardial ischaemia, scar, and function. Its incremental prognostic value in patients with left ventricular (LV) systolic dysfunction remains uncertain. Methods and results: We analysed a prospective multicentre registry of consecutive patients undergoing vasodilator stress perfusion CMR at three French centres (2008–24). Patients with CMR-derived LVEF < 50% were included. The primary end point was all-cause mortality. Associations were estimated with multivariable Cox models. Incremental prognostic value of ischaemia and late gadolinium enhancement (LGE) beyond clinical factors and LVEF was assessed by likelihood ratio χ2, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Among 5977 patients (79% men; age 66 ± 12 years, mean LVEF 42 ± 7%), inducible ischaemia was present in 19% (mean extent 2.4 ± 1.2 segments). Over a median follow-up of 9 years, 1343 patients (22%) died. Ischaemic segment extent was independently associated with mortality (HR per segment 1.11; 95% CI, 1.06–1.15; P < 0.001). Adding ischaemia and LGE to clinical factors and LVEF improved model fit and reclassification (global χ2 increased from 707 to 728; NRI 0.217; IDI 0.004; all P < 0.001). Findings were consistent across LVEF subgroups (40–50% and <40%). In secondary analyses among patients with ischaemia, outcomes differed by subsequent revascularization status; these findings are observational and hypothesis-generating. Conclusion: In patients with LVEF < 50%, ischaemic burden on stress CMR is independently associated with long-term mortality beyond clinical factors, LVEF and LGE. Integrating ischaemia and scar metrics provides incremental prognostic information that may aid risk stratification using stress CMR in LV systolic dysfunction.

  • Concomitant hypertension in hypertrophic cardiomyopathy: clinical phenotype and prognostic associations of cardiovascular magnetic resonance biomarkers

    by Jeremy Florence, Trecy GonçaLves, Solenn Toupin, Suzanne Duhamel, Philippe Garot, Julien Hudelo, Francesca Sanguineti, Thomas Hovasse, Mariama Akodad, Antoinette Neylon, et al.

    Aims: To characterize the cardiovascular magnetic resonance (CMR) phenotype of hypertensive hypertrophic cardiomyopathy (HCM) patients, assess the association between hypertension and all-cause mortality, and compare the long-term prognostic performance of CMR-derived biomarkers between hypertensive and non-hypertensive HCM patients. Methods and results: Between 2008 and 2024, all consecutive HCM patients referred for CMR from the hypertrophic cardiomyopathy-late gadolinium enhancement registry were included. The primary outcome was all-cause mortality. Clinical variables, cardiac volumes, myocardial mass, functions, and tissue characterization with late gadolinium enhancement (LGE) were assessed in all patients. The prognostic value of hypertension and CMR-derived biomarkers were assessed using survival analysis. Among 2873 patients with HCM (52 ± 8 years, 56% males), 796 (28%) had hypertension. Hypertensive HCM patients had greater LGE extent (1.1 ± 1.8 vs. 0.9 ± 1.5, P < 0.001), more LGE multiple locations (17% vs. 11%, P < 0.001), and more midwall LGE (35% vs. 28%, P = 0.001). After 1:1 propensity score matching, survival curves showed an increased risk of all-cause mortality for hypertensive HCM patients over a median follow-up of 9 years [hazard ratio (HR): 1.32, 95% confidence interval (CI): 1.04–1.69; log-rank P = 0.024]. High LGE extent (more than three segments) and septal location of LGE were independently associated with mortality in both hypertensive HCM patients (HR: 3.99, 95% CI: 2.21–7.18; P < 0.001 and HR: 1.76, 95% CI: 1.03–3.01; P = 0.039, respectively) and non-hypertensive HCM patients (HR: 4.63, 95% CI: 2.15–9.97; P < 0.001 and HR: 1.48, 95% CI: 1.02–2.15; P = 0.040, respectively). Conclusion: In a large multicenter cohort of HCM patients, concomitant hypertension was associated with increased long-term mortality, and prognostic associations of CMR-LGE biomarkers were found. These findings highlight the importance of comprehensive cardiovascular risk assessment in HCM patients.

  • Long-term Prognostic Value of Stress Cardiovascular Magnetic Resonance in Patients with Hypertension without known coronary artery disease

    by Sonia Houssany-Pissot, Jérôme Garot, Suzanne Duhamel, Solenn Toupin, Alexandre Unger, Francesca Sanguineti, Stéphane Champagne, Thierry Unterseeh, Bernard Chevalier, Jeremy Florence, et al.

    AIM: Benefits of screening coronary artery disease (CAD) using stress perfusion cardiovascular magnetic resonance (CMR) in patients with hypertension without known CAD is not well established. The aim of our study was to assess the long-term prognostic value of vasodilator stress CMR in patients with hypertension without known CAD. METHODS: Between December 2008 and January 2022, all consecutive patients with hypertension without known CAD referred for stress CMR were followed up to the occurrence of major cardiovascular events (MACE), defined as cardiovascular mortality or non-fatal myocardial infarction (MI). Cox regressions were performed to determine the prognostic value of each parameter. RESULTS: Among 2,019 patients (69 ± 12 years; 45% male) with a median follow up of 6.7 (5.9- 8.9) years, 327 had MACE (16%). Patients without ischaemia experienced a lower rate of MACE than those with ischaemia (12 versus 39%, respectively, p < 0.001). Ischaemia and unrecognised MI were both significantly associated with the occurrence of MACE (respectively, HR: 4.1, 99.5%CI: 3.0-5.7 and HR: 3.6, 99.5%CI: 2.6-5.1, both p < 0.001). After adjustment, both the extent of ischaemia and unrecognised MI were independent predictors of MACE (respectively, HR: 1.2, 99.5%CI: 1.2-1.3, and HR: 1.2, 99.5%CI: 1.1-1.3, both p < 0.001). Adding stress CMR parameters improved model discrimination and reclassification, with greatest improvements in stepwise Model (C-statistic improvement: 0.02; net reclassification improvement: 0.50; integrative discrimination index: 0.02; all p < 0.001). CONCLUSION: In patients with hypertension without known CAD, stress CMR is a long-term predictor for the incidence of MACE and offer an incremental prognostic value over traditional predictors.

  • Prognostic Impact of LGE Granularity Using CMR in End‑Stage Hypertrophic Cardiomyopathy

    by Julien Hudelo, Jérôme Garot, Solenn Toupin, Suzanne Duhamel, Francesca Sanguineti, Philippe Garot, Thomas Hovasse, Stéphane Champagne, Thierry Unterseeh, Mariama Akodad, et al.

    BACKGROUND: End-stage hypertrophic cardiomyopathy (HCM) is a distinct and advanced form of HCM, defined by a left ventricular ejection fraction P =0.02). Each LGE granularity component was independently associated with mortality after adjustment: LGE extent (hazard ratio, 2.85 [95% CI, 1.03–7.85]; P =0.02), septal location (hazard ratio, 1.73 [95% CI, 1.10–2.73]; P P <0.001). CONCLUSIONS: In this large multicenter cohort of patients with end-stage HCM, the LGE granularity model integrating LGE extent, location, and pattern provided strong and independent prognostic value.


  • Open Access

    Incidence and predictors of major arrhythmic events after myocarditis: a systematic review and meta-analysis.

    by Arianna Morena, Federico Giacobbe, Lorenzo Candido-Todesco, Andrea Moretti, Andrea Saglietto, Pier Paolo Bocchino, Jérôme Garot, Matteo Anselmino, Marco Merlo, Gianfranco Sinagra, et al.

    Long-term arrhythmic risk after myocarditis remains uncertain, and optimal management is debated. We aimed to assess the incidence and predictors of major arrhythmic events (MAEs) after myocarditis. We conducted a systematic literature review and meta-analysis including 19 observational studies on myocarditis and MAEs during follow-up. Major arrhythmic events were defined as a composite of sudden cardiac death (SCD), ventricular fibrillation (VF), aborted cardiac arrest (ACA), sustained ventricular tachycardia (sVT), and appropriate implantable cardioverter defibrillator (ICD) or wearable-cardioverter defibrillator (WCD) intervention. The primary outcome was the incidence of MAEs after discharge; secondary outcomes included occurrence of each component of MAEs and the composite of all-cause mortality or heart transplantation (HTx). Three thousand nine hundred and fifty-four patients (71% male, 67% acute, 88% complicated myocarditis) were included. At presentation, 15% had high-grade atrioventricular block (AVB), 31% heart failure, 38% MAEs. At a median follow-up of 24 months (interquartile range 19-57), 28% suffered MAEs, with a median time of presentation of 12 months. The incidence of sVT, ACA/VF, appropriate ICD/WCD intervention, and SCD were 22%, 6%, 20%, and 1%, respectively. The combined rate of all-cause mortality/HTx was 11%. At meta-regression analysis, high-grade AVB, MAEs at presentation, and fulminant myocarditis were associated with higher risk of MAEs during follow-up, while male gender resulted as a protective factor. The incidence of MAEs after a complicated acute myocarditis can be high over time. Further prospective studies are needed to better stratify high-risk patients, identify those with an underlying arrhythmogenic cardiomyopathy, and guide antiarrhythmic strategies.